Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 5/20 | 0.54 |
| ▸ | GBA1 | P04062 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | LRAT | O95237 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22543403 | 1.00 | GJB2 (0.54) | GJB2GBA1MAPK1SPHK2SPHK1 | |
| SCHEMBL11505189 | 0.89 | GJB2 (0.51) | GJB2GBA1MAPK1LRAT | |
| SCHEMBL11505190 | 0.89 | GJB2 (0.51) | GJB2GBA1MAPK1LRAT | |
| SCHEMBL15184676 | 0.84 | MAPK1 (0.53) | GJB2GBA1MAPK1SPHK2SPHK1 | |
| SCHEMBL15184661 | 0.84 | MAPK1 (0.53) | GJB2GBA1MAPK1SPHK2SPHK1 | |
| SCHEMBL15184654 | 0.84 | MAPK1 (0.53) | GJB2GBA1MAPK1SPHK2SPHK1 | |
| SCHEMBL17640864 | 0.83 | MAPK1 (0.61) | GJB2GBA1MAPK1 | |
| SCHEMBL16250422 | 0.83 | MAPK1 (0.61) | GJB2GBA1MAPK1 | |
| SCHEMBL28364147 | 0.83 | MAPK1 (0.61) | GJB2GBA1MAPK1 | |
| SCHEMBL28995607 | 0.83 | MAPK1 (0.61) | GJB2GBA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189438-A1 | DI- and Tri-Cationic Glycosylated Antitumor Ether Lipids, L-Gucosylated Gaels and Rhamnose-Linked Gaels as Cytotoxic Agents Against Epithelial Cancer Cells and Cancer Stem Cells | THE UNIV OF MANITOBA (CA) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189438-A1 | DI- and Tri-Cationic Glycosylated Antitumor Ether Lipids, L-Gucosylated Gaels and Rhamnose-Linked Gaels as Cytotoxic Agents Against Epithelial Cancer Cells and Cancer Stem Cells | UGCG, PNLIP, B3GAT3 | GJB2 4072/4885GBA1 154/4885MAPK1 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.